Systematic review and meta-analysis of the clinical features of MGRS

BMC Nephrology

Table 4 Meta-analysis of clinical features of amyloidosis

Clinical Features	Studies	Effects model	OR/WMD	95%CI	P-value	Heterogeneity
						I²	P-value
Age(year)	4	Random	3.52	1.00-6.05	0.006	51.0	0.106
Sex(%)	4	Fixed	1.14	0.84–1.55	0.389	0.0	0.783
diabetes(%)	2	Random	0.78	0.11–5.46	0.803	81.5	0.020
stage CKD3(%)	2	Fixed	0.26	0.16–0.42	<0.001	10.6	0.290
stage CKD4(%)	2	Fixed	0.44	0.26–0.76	0.003	0.0	0.976
stage CKD5(%)	2	Fixed	0.27	0.13–0.55	<0.001	0.0	0.431
Albumin(g/dl)	2	Random	-0.55	-0.82–0.28	<0.001	63.0	0.100
Hemoglobin(g/dl)	2	Random	1.70	-0.29-3.70	0.094	87.4	0.005
serum creatinine(mg/dl)	3	Random	-0.66	-1.22–0.09	0.023	68.8	0.040
eGFR(ml/min/1.73 m2)	2	Fixed	34.24	27.88–40.59	<0.001	0.0	0.443
complement C3(mg/dl)	2	Fixed	30.78	23.34–38.22	<0.001	0.0	0.635
complement C4(mg/dl)	2	Random	2.48	-8.80-13.76	0.667	86.9	0.006
urinary protein level(g/d)	3	Fixed	2.12	1.46–2.79	<0.001	0.0	0.928
urinary protein ≥ 1.5 g/d(%)	2	Fixed	7.08	3.80-13.18	<0.001	0.0	0.609
nephrotic range proteinuria(%)	2	Fixed	3.65	2.28–5.85	<0.001	0.0	0.335
hematuria(%)	2	Random	0.31	0.11–0.85	0.023	69.5	0.070
monoclonal(%)	2	Fixed	1.33	0.49–3.60	0.569	0.0	0.877
bi-clonal(%)	2	Fixed	0.75	0.28–2.02	0.569	0.0	0.877
k-chain value(mg/l)	2	Random	-8.99	-22.81-4.83	0.202	81.8	0.019
λ-chain value(mg/l)	2	Random	8.72	-3.42-20.87	0.159	85.1	0.010
abnormal free light chain ratio(%)	2	Fixed	3.71	1.82–7.56	<0.001	0.0	0.405
bone marrow puncture rate(%)	2	Fixed	1.09	0.53–2.24	0.806	12.9	0.284
abnormal bone marrow outcome rate(%)	2	Fixed	4.30	1.80-10.28	0.001	0.0	0.910

ISSN: 1471-2369